Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoetic stem cells in a patient in need thereof.

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Abstract: Provided herein are antibodies to DC-SIGN, conjugates of DC-SiGN antibodies, and DC-SiGN antibody fusion proteins and the use of such antibodies, conjugates, and fusion proteins for the treatment of diseases such as cancer.

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Abstract: A method of preparing a porous and permeable adsorption material for a vaporizer utilizes a mixing step; a kneading step; a molding step; a drying step; a first holding step; a calcining step; a second holding step; a forming step; a third holding step; and a producing step. The raw materials include particulates of silicon carbide of 50-85 weight percent, a binder of 1-30 weight percent, a pore forming agent of 5-35 weight percent, and a surfactant of 0.15-7.5 weight percent. Once these raw material components are mixed, then adding water of 5 weight percent to 35 weight percent while kneading to form a wetted mixture of raw materials. The remaining steps describe a molding and heating regimen.

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

Abstract: A bio-based coating for a building automatically transmits or reflects heat gain from infrared sunlight. The coating is composed of bio-based polymerized oil and a catalyst that is also a thermochromic material. The catalyst reduces the temperature for polymerization of the oil to create a suspension that forms a hardened mixture when cooled below about 100 degrees Centigrade. The thermochromic properties of the catalyst are operable to switch the hardened mixture from transparent to reflective of infrared light when the temperature rises above a switching temperature in an approximate range of 18 degrees Centigrade to 35 degrees Centigrade. The method of using the coating involves spraying a hot bio-based coating on the roof surface and allowing it to cool. The method of making involves heating the suspension to a reaction temperature, holding at the reaction temperature, and, introducing an air flow through the mixture at the reaction temperature.

Abstract: A bio-based adhesive and method of making the adhesive replaces or serves as additives for asphalt, sealant, and polymers such as styrene-butadiene-styrene and atactic polypropylene in the manufacture of building or paving materials. The method includes steps of forming a mixture of oil comprising fatty acids group and optionally a powdered material; maintaining the oil-to-powdered-material weight ratio in the mixture between 1 to 0.00001 and 1 to 20; heating the mixture to a reaction temperature greater than 55 degrees Centigrade; maintaining the reaction temperature until the oil is polymerized; and, injecting air into the mixture while polymerizing the oil. The adhesive of this method comprises a renewable polymer and the powdered material.

Abstract: A bio-based adhesive and method of making the adhesive replaces or serves as additives for asphalt, sealant, and polymers such as styrene-butadiene-styrene and atactic polypropylene in the manufacture of building or paving materials. The method includes steps of forming a mixture of oil comprising fatty acids group and optionally a powdered material; maintaining the oil-to-powdered-material weight ratio in the mixture between 1 to 0.00001 and 1 to 20; heating the mixture to a reaction temperature greater than 55 degrees Centigrade; maintaining the reaction temperature until the oil is polymerized; and, injecting air into the mixture while polymerizing the oil. The adhesive of this method comprises a renewable polymer and the powdered material.

Abstract: An adhesive product and method of making the product replaces asphalt in the manufacture of roofing shingles and pavement. The method comprises steps of forming a mixture of oil comprising fatty acids and a powdered material; maintaining the oil to powdered material weight ratio in the mixture between 1 to 0.01 and 1 to 4.9; heating the mixture to a reaction temperature greater than 100 degrees Centigrade; maintaining the reaction temperature for at least five minutes; and, injecting air into the mixture while maintaining the reaction temperature. In making a roofing shingle, the method includes additional steps of: applying the heated mixture to a fiberglass mat sheet from an upstream roll to form a tacky coated strip; and, adding a layer of granules to the tacky coated strip. The adhesive material of this method comprises polymerized oil and the powdered material.

Abstract: An adhesive product and method of making the product replaces asphalt in the manufacture of roofing shingles. The method comprises steps of forming a mixture of oil comprising fatty acids and a powdered catalyst operable to catalyze the polymerization of the oil; maintaining the oil to powdered catalyst weight ratio in the mixture between 1 to 0.01 and 1 to 4.9; heating the mixture to a reaction temperature greater than 100 degrees Centigrade; maintaining the reaction temperature for at least five minutes; and, injecting air into the mixture while maintaining the reaction temperature. In making a roofing shingle, the method includes additional steps of: applying the heated mixture to a fiberglass mat sheet from an upstream roll to form a tacky coated strip; and, adding a layer of granules to the tacky coated strip. The adhesive material of this method comprises polymerized oil and the powdered catalyst.

Abstract: This invention provides novel methods and compositions for modulating T cell differentiation and T cell responses. The modulators are identified by screening test compounds for ability to modulate an inositol 1,4,5-trisphosphate 3-kinase (IP3K). The IP3K modulators can be further examined for their activity in modulating development of progenitor T cells (e.g., CD4+/CD8+ double positive T cells) into mature CD4+ or CD8+ single positive T cells. Pharmaceutical compositions comprising these T cell modulators can be administered to a subject to modulate T cell immune responses, to suppress inflammations, and to treat disease conditions such as autoimmune diseases, graft rejection or allergies.

Abstract: This invention provides novel methods and compositions for modulating T cell differentiation and T cell responses. The modulators are identified by screening test compounds for ability to modulate an inositol 1,4,5-trisphosphate 3-kinase (IP3K). The IP3K modulators can be further examined for their activity in modulating development of progenitor T cells (e.g., CD4+/CD8+ double positive T cells) into mature CD4+ or CD8+ single positive T cells. Pharmaceutical compositions comprising these T cell modulators can be administered to a subject to modulate T cell immune responses, to suppress inflammations, and to treat disease conditions such as autoimmune diseases, graft rejection or allergies.